Nykredit A S Takes $3.22 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Nykredit A/S acquired 37,377 Zimmer Biomet shares in the second quarter, establishing a position valued at approximately $3.22 million. Institutional investors collectively own 88.89% of the company.
• Analyst sentiment remains mixed but leans neutral: six analysts rate the stock a Buy, 14 a Hold, and two a Sell, resulting in a consensus “Hold” rating and a $103 price target.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in adjusted EPS and $2.18 billion in revenue, while revenue rose 4.8% year over year. The company also declared a quarterly dividend of $0.24 per share, equivalent to a 1.0% annualized yield.

Nykredit A S acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 37,377 shares of the medical equipment provider's stock, valued at approximately $3,218,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Amundi lifted its stake in Zimmer Biomet by 28.8% in the 2nd quarter. Amundi now owns 719,279 shares of the medical equipment provider's stock valued at $61,923,000 after buying an additional 160,765 shares in the last quarter. Studio Investment Management LLC grew its holdings in shares of Zimmer Biomet by 17.3% during the 2nd quarter. Studio Investment Management LLC now owns 22,209 shares of the medical equipment provider's stock worth $1,917,000 after purchasing an additional 3,282 shares during the period. Ameritas Advisory Services LLC purchased a new position in Zimmer Biomet during the second quarter worth about $101,000. HB Wealth Management LLC increased its holdings in Zimmer Biomet by 7.2% in the 2nd quarter. HB Wealth Management LLC now owns 18,538 shares of the medical equipment provider's stock valued at $1,596,000 after purchasing an additional 1,249 shares during the last quarter. Finally, Saudi Central Bank grew its stake in shares of Zimmer Biomet by 85.2% in the second quarter. Saudi Central Bank now owns 13,550 shares of the medical equipment provider's stock valued at $1,167,000 after buying an additional 6,235 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Stifel Nicolaus increased their price objective on Zimmer Biomet from $105.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Royal Bank Of Canada lifted their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Truist Financial boosted their price objective on Zimmer Biomet from $92.00 to $106.00 and gave the company a "hold" rating in a research note on Thursday, August 6th. Finally, BMO Capital Markets reaffirmed a "market perform" rating and issued a $96.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Six analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $103.00.

Insider Activity

In other Zimmer Biomet news, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares in the company, valued at $6,415,468.85. The trade was a 4.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the business's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is owned by insiders.

Zimmer Biomet Price Performance

ZBH stock opened at $94.10 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The firm has a market cap of $17.95 billion, a P/E ratio of 22.90, a PEG ratio of 1.78 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $106.88. The stock's 50 day moving average price is $96.30 and its 200 day moving average price is $91.31.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet's payout ratio is currently 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc NYSE: ZBH is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.